DWTX

Dogwood Therapeutics, Inc. is a biotechnology company operating within the healthcare sector. With a market capitalization of $125.45 million and 12 employees, it falls into the biotechnology industry category. The financial health of Dogwood Therapeutics, Inc. indicates significant challenges. The company reported net income of -$39,975,560 (TTM), which is an alarming figure. Additionally, its gross margin, operating margin, and profit margin are all at 0.0%. This suggests that the company has not been generating sufficient revenue to cover expenses, resulting in substantial losses. Furthermore, the return on equity and return on assets are -931.0% and -42.0%, respectively, indicating significant underperformance. The balance sheet shows a debt-to-equity ratio of 2.41, with $174,778 in debt against $10.13 million in cash. The valuation context for Dogwood Therapeutics, Inc. presents mixed signals. With a forward P/E ratio of -0.66 and price to book value of -0.29, the stock appears to be trading at an extremely low multiple relative to its net asset value. However, without available data on revenue growth or earnings growth, it is challenging to assess the company's long-term prospects. The dividend yield is N/A, and the payout ratio is 0.0%.